思密达干预新生儿黄疸的临床研究

Observation of sinecta interferin in neonate myotomia

目的:探讨思密达口服干预新生儿期黄疸的临床疗效。方法:随机分为干预组和对照组,两组都于生后0.5h内开始喂奶,干预组口服思密达1.0g,以后每8h一次,连用7d,两组每隔一天查胆红素一次。结果:干预组发生黄疸≥Ⅲ级的例数与对照组相比,有显著性差异(X^2=5.22,P<0.05);干预组无肉眼黄疸的例数与对照组相比,亦有显著性差异(X^2=5.97,P<0.05);干预组黄疸持续时间,与对照组比较有非常显著性差异(t=3.35,P<0.001)。结论:提早开奶加思密达口服可减少新生儿胆红素异常升高,缩短黄疸时间,减少胆红素对神经系统损伤的危险性。

Objective: To study clinic effect of smecta in interfering with neonate mytoma. Methods: The cases with neonate myotomia were randomly divided into two groups. Interference group were treated with smecta, 1.0g, q8h×87d; control group with nothing. All the newborns in both groups were fed half an hour after birth. The bilirubin was tested once two days for both groups. Results: The amount of jaundice in interference group's( ≥ Ⅲ ) was significant less than that in control group(x2 = 5. 22, P < 0. 05); the cases of no visible jaundice to the naked eye were significantly more than those in control group (x2 = 5. 97, P < 0. 05). And the jaundice in interference group lasted much shorter than that in control group( t = 3. 35, P < 0. 001). Conclusion: Feeding earlier with smecta could reduce neonate myotomia, shorten the time of jaundice and lessen the nerve's damage cacesed by the bilirubin.